Top Page
Recce Pharmaceuticals Ltd.
(Sydney:RCE)
Recce Pharmaceuticals Ltd. (RCE) vs. iShares MSCI Australia ETF (EWA)
Recce Pharmaceuticals Ltd. Business Overview & Revenue Model
Recce Pharmaceuticals Ltd. Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 7.51M | 5.03M | 4.37M | 3.08M | 1.64M |
| Gross Profit | -2.94M | -2.19M | 4.15M | 2.90M | 1.34M |
| EBITDA | -20.33M | -21.35M | -16.99M | -13.87M | -14.77M |
| Net Income | -21.43M | -17.66M | -13.08M | -10.99M | -13.51M |
Balance Sheet | |||||
| Total Assets | 12.41M | 6.37M | 2.56M | 12.62M | 21.68M |
| Cash, Cash Equivalents and Short-Term Investments | 10.45M | 4.42M | 1.56M | 11.58M | 20.87M |
| Total Debt | 10.77M | 811.19K | 250.57K | 74.76K | 126.95K |
| Total Liabilities | 15.47M | 15.89M | 5.14M | 2.56M | 1.18M |
| Stockholders Equity | -3.05M | -9.52M | -2.59M | 10.06M | 20.50M |
Cash Flow | |||||
| Free Cash Flow | -20.47M | -13.15M | -12.73M | -9.05M | -7.93M |
| Operating Cash Flow | -20.44M | -13.01M | -12.69M | -9.01M | -7.86M |
| Investing Cash Flow | -443.90K | -141.90K | -38.63K | -40.34K | -76.01K |
| Financing Cash Flow | 26.92M | 16.00M | 2.71M | -240.50K | 26.12M |
Recce Pharmaceuticals Ltd. Technical Analysis
Recce Pharmaceuticals Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | AU$44.16M | ― | -49.72% | ― | ― | 10.78% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | AU$119.63M | ― | -42.68% | ― | ― | 63.46% | |
| ― | AU$117.12M | ― | ― | ― | ― | 0.66% | |
| ― | AU$113.90M | ― | -83.09% | ― | ― | 55.94% | |
| ― | AU$64.13M | ― | -41.60% | ― | ― | 4.07% | |
| ― | AU$107.88M | -13.24 | -47.98% | ― | 700.00% | 26.88% |
Recce Pharmaceuticals Ltd. Corporate Events
Recce Pharmaceuticals Ltd announced a change in the director’s interest, specifically concerning James Graham, who has disposed of 745,962 Class B Performance Shares through a selective buy-back approved by shareholders. This change reflects a strategic adjustment in the company’s equity structure, potentially impacting its market positioning and shareholder value.
The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.
Recce Pharmaceuticals Ltd has announced the cessation of 8,754,423 performance shares due to a selective buy-back, effective October 7, 2025. This move may impact the company’s capital structure and could be part of a strategic effort to optimize shareholder value and streamline operations, signaling potential shifts in their market positioning.
The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.
Recce Pharmaceuticals Ltd has announced the final notification of its selective buy-back of performance shares, totaling 8,754,423 securities at a consideration of AUD 87.54. This strategic move is likely to impact the company’s financial structure and could influence its market positioning by potentially increasing shareholder value.
The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.
Recce Pharmaceuticals Ltd has announced an update regarding its selective buy-back of performance shares, identified by the ASX security code RCEAH. The update pertains to the date of the buy-back occurring, which has been changed from the initially notified date. This announcement could impact stakeholders by altering the timeline of the buy-back process, potentially affecting the company’s share structure and market perception.
The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.
Recce Pharmaceuticals Ltd announced the dispatch of documents related to its 2025 Annual General Meeting to shareholders. The company’s innovative anti-infective solutions, which have garnered significant recognition, position it as a key player in addressing global health challenges related to antibiotic resistance. The upcoming meeting is set to discuss these advancements and their implications for stakeholders.
The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.
Recce Pharmaceuticals has commenced patient dosing in its Registrational Phase 3 clinical trial for diabetic foot infections (DFI) in Indonesia, with five clinical sites activated. This trial, one of the largest DFI studies globally, aims to assess the efficacy of RECCE 327 Topical Gel (R327G) and is expected to have interim results by Q1 2026. The trial is strategically significant given Indonesia’s high diabetes prevalence, representing a substantial market opportunity. Successful results could lead to accelerated approval and a potential commercial launch in 2026, positioning Recce as a key player in addressing diabetes-related infections.
The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.
Recce Pharmaceuticals Ltd has announced its Annual General Meeting scheduled for November 5, 2025, with the closing date for director nominations set for September 23, 2025. This announcement underscores the company’s ongoing commitment to advancing its anti-infective pipeline, which has garnered significant attention from global health authorities for its potential to address critical health challenges posed by resistant pathogens.
The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.
Recce Pharmaceuticals Ltd announced the issuance of 4,634,304 unquoted warrants set to expire on July 30, 2030. This issuance is part of previously announced transactions and reflects the company’s ongoing efforts to strengthen its financial position, potentially enhancing its operational capabilities and market competitiveness.
The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.
Recce Pharmaceuticals Ltd announced that its RECCE® 327 Topical Gel (R327G) has shown statistically significant positive efficacy against Methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa in rat infection models. The study demonstrated that R327G not only reduced bacterial load significantly but also accelerated wound healing compared to the standard antibiotic Soframycin. This development supports ongoing collaboration with the U.S. Department of Defense, including a US$2M grant and a Cooperative Research and Development Agreement with the US Army Medical Research Institute of Infectious Diseases. The results suggest that R327G could offer a more effective and convenient treatment option for burn wounds, potentially benefiting patients, clinicians, and healthcare economics.
Recce Pharmaceuticals Ltd announced its participation in the 2025 Military Health System Research Symposium, where it will present findings on its synthetic anti-infective, RECCE® 327. The research highlights the compound’s efficacy against multiple bioterrorism pathogens, including Anthrax and Plague, showcasing its potential as a novel countermeasure in biodefense. This development is part of a Cooperative Research and Development Agreement with the US Army Medical Research Institute of Infectious Diseases, underscoring the importance of innovative solutions in military and public health strategies.
Recce Pharmaceuticals Ltd has reported significant progress in its clinical trials and strategic partnerships. The company has expanded its Phase 3 clinical trial sites in Indonesia and received additional approval for its Phase 2 trial, allowing more diabetic foot infection patients access to its R327G topical gel. This follows positive results in previous trials, indicating high efficacy. Additionally, Recce has entered into a Cooperative Research and Development Agreement with the US Army Medical Research Institute of Infectious Diseases, enhancing its research capabilities against biodefense pathogens. The company has also secured substantial funding through a capital raise and a non-dilutive financing agreement, strengthening its financial position.